the pharmaceutical industry is devoting huge resources to cancer research and development in relation to sales of existing drugs although reliable figures are not available industry sources estimate that companies worldwide spend dollars 3bn pounds 2bn a year on cancer rd us companies are responsible for about half the total the cancer therapeutics market is worth about dollars 65bn this year according to frost sullivan the international market research company 38 per cent in the us 26 per cent in europe and 36 per cent in the rest of the world the leading suppliers are zeneca of the uk whose tamoxifen was the best sellingcancer drug with dollars 550m sales in 1993 and bristolmyers squibb of the us devoting almost 50 per cent of sales revenues to rd is a very high figure indeed says david barrett bristolmyers squibbs strategic projects director the industrys overall rd expenditure is 15 per cent of drug sales the main reason why cancer spending is so high is that the disease is top of the industrys priority list of unmet needs although deaths from heart disease are twice those from cancer they are falling and cardiologists already have a much wider range of effective treatments than oncologists at the same time scientific advances are giving many new leads both to traditional drug companies and to the emerging biotechnology sector the world now has more than 1000 experimental cancer drugs in the rd pipeline analysts such as decision resources and frost sullivan predict continued growth of more than 10 per cent a year in the cancer market into the next century it is expected to exceed dollars 10bn by 1998 the industrys cancer rd spending is matched by a further dollars 3bn a year from the worlds governments and charities by far the largest contributor is the us national cancer institute which receives dollars 2bn a year in federal funding the charitable sector is particularly important in the uk where the imperial cancer research fund and cancer research campaign spend pounds 100m a year between them 10 times as much as the statefunded medical research council